Realising The World Health Organisation Targets For Elimination Of Cervical Cancer As A Public Health Problem: Effective Implementation And Scale-up Of HPV Vaccination And Cervical Screening In Australia, Regionally, And Globally
Funder
National Health and Medical Research Council
Funding Amount
$2,125,000.00
Summary
This fellowship focuses on improving cancer screening, particularly the implementation of HPV vaccination and cervical screening. CI Canfell will pursue an Australian, regional and global health agenda towards the elimination of cervical cancer. Her work is supporting the successful implementation of the new cervical screening program in Australia, provides crucial support to other countries in the region, and is directly informing the WHO global elimination strategy.
3D-BrachyView: A 3D Real-time Virtual Reality Intra-operative Quality Assurance System For Brachytherapy
Funder
National Health and Medical Research Council
Funding Amount
$359,105.00
Summary
3D-Brachyview aims to bring 3D virtual reality into the Quality Assurance and training of physicists in prostate cancer brachytherapy. The 3D simultaneous visualisation of the position of the seeds implanted, the actual shape and position of the prostate, and the expected treatment plan, will help doctors to deliver the best treatment possible.
Ovarian and endometrial cancer affect >3,200 women each year in Australia and 3 or 4 women die from these cancers every day. The overall aim of my program of research is to reduce the burden of these cancers in future generations of Australian women by increasing our understanding of (i) what causes them, (ii) how we can optimise patient management to enhance patient outcomes and (ii) how lifestyle changes might improve quality and life and survival, for women who are diagnosed with them.
Generating The Evidence To Control Cancer And Optimise Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$6,564,341.00
Summary
Our Program addresses the public health aspects of common cancers, particularly cancers of the skin and gynaecological tracts. Each year in Australia, nearly 400,000 people are treated for skin cancer, and more than 3,500 women develop ovarian or uterine cancer. Our aims are first, to understand how we might prevent these cancers in the future; second, to enhance diagnosis of these cancers; and third, to improve the survival and quality of life for people who are diagnosed with these cancers
A Vulvar Cancer Cluster Caused By Genetic Susceptibility: Investigating The Genetic Mechanism.
Funder
National Health and Medical Research Council
Funding Amount
$1,154,342.00
Summary
Cancer of the vulva is 70 times more common in young Aboriginal women in Arnhem Land than in other women. Human Papillomavirus (HPV), which also causes cervical cancer, is the usual cause of this cancer; initial investigations have found that HPV is present in these cancers but is not the reason for the excessive incidence. This study will investigate inherited risk factors contributing to the development of this disease in this population.
An Oral Loading Test To Predict Susceptibility To Fluoropyrimidine Drug Toxicity
Funder
National Health and Medical Research Council
Funding Amount
$225,525.00
Summary
Side-effects from anticancer drugs can be unpleasant, but may be deadly if a patient's genes are wrong for the drugs. A common chemotherapy drug, fluorouracil, can be very dangerous, but there's no simple way to predict this. We developed a simple test in which a small amount of a natural chemical is swallowed before chemotherapy. The results should allow the doctor to predict if a patient will suffer serious side effects on fluorouracil, so the dose can be reduced, or another drug tried.
Using Epidemiological Methods To Investigate How Genetic, Environmental And Lifestyle Factors Influence Cancer Incidence And Cancer Survivorship; And Translation Into Cancer Prevention And Policy Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$421,747.00
Summary
This research program focuses on investigating genetic, environmental and lifestyle causes of cancer, preventing new cases of cancer, and improving outcomes after a cancer diagnosis, particularly for melanoma and gynaecological cancer, which carry a heavy burden in the Australian population. The research will also inform the best allocation of health system resources for cancer control, and ensure translation of research findings into cancer prevention, clinical practice and policy outcomes.
Pyk2: A Central Mediator Of Gonadotropin Action In Ovarian Cancer
Funder
National Health and Medical Research Council
Funding Amount
$334,053.00
Summary
Ovarian cancer generally presents at an advanced stage where 5 yr survival is less than 25%. Elevated levels of specific hormones after menopause may increase the risk of this cancer. We have shown that a protein called Pyk2 is activated in response to these hormones and may have significant roles in ovarian cancer cell migration, invasion and proliferation. This project will investigate the role of this protein, with the goal of improved therapeutics for women with ovarian cancer.
Rectal Invivo Radiotherapy Dosimetry Using A Fibre Optic Array
Funder
National Health and Medical Research Council
Funding Amount
$438,963.00
Summary
For pelvic cancer patients too much radiation causes rectal problems which are hard to avoid. To reduce the problem we have developed a tiny dosimeter, which we will network to measure the radiation in the rectum as it is being received. This will tell us the maximum safe dose of radiation we can give before causing rectal complications. This will be an effective quality assurance and radiation safety tool.
Contribution Of Ovarian Cancer Stem Cells To Chemoresistance And Recurrent Disease.
Funder
National Health and Medical Research Council
Funding Amount
$378,940.00
Summary
Ovarian cancer is the most lethal gynaecological cancer. Previously, we showed that cancer stem cells are the “beating heart” of the ovarian cancer and are responsible for drug resistance and tumour relapse. The ineffective targeting of these cells by chemotherapy is accountable for the poor clinical outcomes in ovarian cancer patients. This project will define the molecular signals involved in maintenance of cancer stem cells and develop targeted therapies against these cells.